Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
A new once-daily experimental pill slowed the decline in memory, thinking, and everyday functioning by 31% in some people with Alzheimer's disease in a Phase 3 trial.
Developed by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression by the equivalent of 3.5 months over one year.
Unlike existing dementia drugs, which primarily alleviate symptoms, AR1001 has shown potential to slow disease progression.
However, the benefit was significant only among patients who were not taking other dementia medications.
The company announced that "the trial had met its primary endpoint" at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, US.
Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For
The global trial involved 1,535 people with Alzheimer's disease across 230 sites in 13 countries.
Researchers assessed participants using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, judgment and the ability to perform everyday activities.
The findings showed:
The findings suggest that AR1001's effectiveness may depend on whether patients are taking other Alzheimer's medications.
Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, described the results as encouraging.
"These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms," Dr Richard said, the Daily Mail reported.
"Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third," he added.
Read More: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
AR1001 works differently from existing Alzheimer's treatments, such as lecanemab and donanemab, which target amyloid plaques in the brain.
Its active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, the compound used in Viagra to treat erectile dysfunction.
Both drugs inhibit an enzyme called phosphodiesterase-5 (PDE5). This helps relax blood vessels and improve blood flow.
Researchers believe AR1001 may have several effects in the brain, including:
Unlike some existing disease-modifying treatments that require infusions or injections, AR1001 is designed as a once-daily oral medication.
However, the drug is from the same family of medicines as Viagra and is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.
Most side effects reported during the trial were mild to moderate. Common side effects included diarrhoea, falls and dizziness.
Severe adverse events occurred in 10% of the treatment group and 9.8% of the placebo group.
Researchers also reported changes in biomarkers associated with Alzheimer's disease. Levels of the protein p-tau217 decreased in the monotherapy group, while cerebrospinal fluid cGMP levels increased in both treatment groups.
These findings offer clues about the drug's biological activity, although further research is needed to establish its effects.
However, the lack of a statistically significant benefit among people taking other Alzheimer's medications, adding that this required further investigation.
AR1001 is not yet available to the public and must undergo regulatory assessment before it can be prescribed.
Regulatory approval will depend on further evaluation, including whether the FDA considers the monotherapy results sufficient to support the drug's approval.
Credit: AI-generated image
L'Oréal USA and other manufacturers of chemical hair relaxers have reached a settlement with four women who alleged that years of using hair straightening products contributed to their gynaecological cancers.
The settlement was made during the first US trial involving these claims, bringing newfound attention to research examining the health risks of chemical hair treatments.
According to Reuters, the four women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, settled their lawsuits for an undisclosed amount. The trial was being held in Chicago.
The women had sued L'Oréal's US subsidiary and several other manufacturers in 2023 and 2024, alleging that prolonged exposure to chemical hair straighteners caused their cancers.
The settlement comes as litigation involving these products continues to surface. More than 12,700 related cases have been consolidated before a federal judge in Chicago.
The products, sold under brand names including Dark and Lovely and Optimum, have been widely marketed to Black women.
Also read: What Is Viral Heightmaxxing? US Doctors Warn Teen Boys Against Taking Cancer Drug To Grow Taller
L'Oréal has maintained that its products are safe. A company spokesperson said, "L’Oréal USA strictly follows all regulations in every market in which it operates and its products are always subject to a rigorous scientific evaluation of their safety."
The company has also argued that existing research does not establish that its products caused the conditions alleged in the lawsuits.
Scientific interest in the health effects of chemical hair straighteners increased after a 2022 study by researchers at the US National Institutes of Health (NIH).
Published in the Journal of the National Cancer Institute, the study examined data from 33,497 women aged 35-74 participating in the Sister Study.
Over an average follow-up of nearly 11 years, 378 cases of uterine cancer were identified.
Researchers found that women who reported using chemical hair straightening products more than four times in the preceding year had more than twice the risk of developing uterine cancer compared to women who had never used them.
The study estimated that 1.64% of women who had never used hair straighteners would develop uterine cancer by age 70, compared to 4.05% among frequent users.
However, researchers did not focus on the specific brands or chemical ingredients used, meaning they could not identify which substances might have contributed to the observed association.
Also read: Can A 'Sponge On A String' Test Help Detect Oesophageal Cancer Before Symptoms?
Other studies have also investigated links between chemical hair treatments and reproductive cancers.
A 2021 study published in Carcinogenesis found that frequent use of hair straighteners and relaxers may cause an increased risk of ovarian cancer. Women who used these products more than four times a year had approximately twice the risk compared with non-users.
Research from the Sister Study cohort has also showed an increased risk of breast cancer due to frequent hair straightener use especially among women who used the products regularly.
However, the findings are not the same across all studies. A 2025 systematic review examining evidence among Black women in the US concluded that the epidemiological evidence that is available did not support an increased risk of breast, ovarian or uterine cancers due to hair relaxer use.
Chemical hair relaxers and straighteners contain different substances depending on their formulation. Some products may contain endocrine-disrupting chemicals, including phthalates and parabens, which can interfere with hormonal activity.
Other concerning chemicals include formaldehyde and certain preservatives. Some straightening treatments can release formaldehyde, a recognised carcinogen.
Researchers have suggested that exposure to endocrine-disrupting chemicals could affect hormonal tissues.
Credit: AI-generated image
The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.
The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.
RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.
The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.
Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.
Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.
Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.
The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.
According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.
Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.
The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.
Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients
The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.
The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.
Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.
Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.
The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.
© $2026 Times Horizon Private Limited